Saturn V Capital Management LLC Crinetics Pharmaceuticals, Inc. Transaction History
Saturn V Capital Management LLC
- $265 Billion
- Q2 2024
A detailed history of Saturn V Capital Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Saturn V Capital Management LLC holds 479,681 shares of CRNX stock, worth $24.2 Million. This represents 8.12% of its overall portfolio holdings.
Number of Shares
479,681
Previous 660,143
27.34%
Holding current value
$24.2 Million
Previous $30.9 Billion
30.47%
% of portfolio
8.12%
Previous 12.39%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
244Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$314 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$308 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$233 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$227 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$222 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.71B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...